Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | 0 Decreased by -100% | -1 Increased by +100% |
| Feb 22, 24 | 2.39 Increased by +175.63% | -1.18 Increased by +302.54% |
| Nov 2, 23 | 0.39 Increased by +18.18% | -0.62 Increased by +162.9% |
| Aug 3, 23 | 0.08 Increased by +127.59% | -0.7 Increased by +111.43% |
| May 4, 23 | 0.39 Increased by +292.6% | -0.87 Increased by +144.28% |
| Feb 23, 23 | -3.16 Decreased by -1.36 K% | -0.64 Decreased by -393.75% |
| Nov 3, 22 | 0.33 Increased by +133.33% | -1.05 Increased by +131.43% |
| Aug 4, 22 | -0.29 Increased by +70.41% | -0.66 Increased by +56.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 120.03 M Decreased by -11.88% | 25.83 M Increased by +19.84% | Increased by +21.52% Increased by +35.99% |
| Jun 30, 23 | 149.95 M Increased by +8.97% | 5.1 M Increased by +126.81% | Increased by +3.4% Increased by +124.6% |
| Mar 31, 23 | 178.87 M Increased by +31.19% | 23.21 M Increased by +274.36% | Increased by +12.97% Increased by +232.91% |
| Dec 31, 22 | 95.12 M Decreased by -43.04% | -207.21 M Decreased by -1.37 K% | Decreased by -217.84% Decreased by -2.32 K% |
| Sep 30, 22 | 136.2 M Increased by +112.17% | 21.55 M Increased by +133.36% | Increased by +15.82% Increased by +115.72% |
| Jun 30, 22 | 137.61 M Decreased by -1.55% | -19.03 M Increased by +70.42% | Decreased by -13.83% Increased by +69.96% |
| Mar 31, 22 | 136.35 M Increased by +19.72% | -13.31 M Decreased by -242.19% | Decreased by -9.76% Decreased by -218.77% |
| Dec 31, 21 | 166.99 M Increased by +15.59% | 16.35 M Increased by +128.24% | Increased by +9.79% Increased by +124.43% |